Kymera Therapeutics (KYMR) PT Raised to $97 at Brookline Capital Markets

June 8, 2026 1:05 PM

Brookline Capital Markets analyst Leah Rush Cann raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $97.00 (from $91.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found